During the first year of the outbreak
of the COVID-19 pandemic,
many drugs and drug candidates have been evaluated as treatment options.
None yet has proved to be an effective cure, but progress in controlling
the disease has been made. In June 2020 we published an article that
described the mechanistic rationale behind the repurposing of seven
licensed drugs in clinical trials for the treatment of COVID-19 and
reviewed synthetic routes to these drugs. Several developments have
occurred since then. Remdesivir (trade name Veklury) has been approved
for use in the U.S. and Europe. Dexamethasone, a steroid drug first
approved in 1959, has shown mortality reduction in severe COVID patients.
Molnupiravir, a new and promising oral antiviral drug, is being studied
in late-stage clinical trials. In this review, we update synthetic
work that has been recently published on remdesivir, provide an overview
of several routes to molnupiravir, and review classical routes to
dexamethasone as well as some of those more recently developed.